Active Hydrophilic Graphene Oxide Nanocomposites Delivery Mediated by Adipose-Derived Stem Cell for Elevated Photothermal Therapy of Breast Cancer

• Published in: International journal of nanomedicine 2023-01, Vol.18, p.971-986
• Main Authors: Peng, Zhangsong, Chang, Qiang, Xing, Malcolm, Lu, Feng
• Format: Article
• Language: English
• Subjects: Ablation; Ablation (Surgery); Acids; Adipocytes; adipose-derived stem cells; Animals; B cells; Body fat; Bone marrow; Breast cancer; Cancer; Care and treatment; Ethylene glycol; Folic Acid; Graphene; graphene oxide; Graphite; Health aspects; Liposuction; Mice; nanocomposite; Nanocomposites; Nanocomposites - therapeutic use; Nanomaterials; Neoplasms; Original Research; Photothermal Therapy; Physiological aspects; Physiology; Polyethylene glycol; Polyethylene Glycols; Radiation; Stem cells; Transplantation; Vitamin B
• ISSN: 1178-2013; 1176-9114; 1178-2013
• DOI: 10.2147/IJN.S380029

Graphene oxide (GO) and its derivatives have recently been identified as promising candidates for early disease diagnosis and therapy. However, the physiological stability and precise launch requirements present limitations on further clinical practices. Adipose-derived stem cells (ADSCs) were employed as an unobstructed biological vehicle to address the validate this ADSC-based tumor-targeting system for highly efficient GO delivery combined with two-stage NIR radiation for superior tumor ablation. GO was modified with poly-ethylene glycol (PEG) and folic acid (FA). Afterward, the GO nanocomposite was internalized into ADSCs. The GO-PEG-FA-laden ADSCs were injected into the tail veins of the tumor-bearing mice. Subsequently, first-stage NIR radiation was utilized to disrupt the ADSCs for GO-PEG-FA release. After this, the heat generated by secondary-stage NIR radiation destroy the malignant cells and shrink the tumor, and the cascade process could be recycled until complete tumor ablation if necessary. The GO-PEG-FA nanocomposite exhibited negligible cytotoxicity and could be internalized into ADSCs to target specific tumor sites after 32 days of intravenous injection. The nanocomposite was released from the ADSCs and taken up into cancer cells again with the assistance of FA after the first dose of near-infrared radiation. Then, the second radiation dose could directly strike the cancer cell for cancer ablation. In summary, we reported a stem cell-based anticancer system that used GO-PEG-FA-laden ADSCs for breast cancer therapy through NIR treatment in mice potentially opens a new avenue not only to address precise drug targeting in tumor therapy, but also future clinical practice in diverse areas.